Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b / 2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

Everest Medicines China California

Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission.In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24.EVER001 was generally safe and well tolerated. No clinically significant adverse events typically associated with earlier-generation BTK inhibitors, such as bleeding, arrhythmia, severe infection, leukopenia, thrombocytopenia, or severe liver function impairment, were reported.
Webcast Link: https://www.acecamptech.com/meeting_live/70512679/774680?event_id=60510700

Alternatively, participants may dial in to the conference call using below dial-in information:

United States:           [phone] (EN)
Chinese Mainland:    [phone] (EN)
                                  [phone] (CN)
Hong Kong, China:    [phone] (EN)
                                  [phone] (CN)
United Kingdom:        [phone] (EN)
International:             [phone] (EN)
Password:                 842080

For Mandarin Session:
Time: 10:30 AM Beijing Time, Wednesday, Dec. 4, 2024 (9:30 PM U.S. Eastern Time on Dec. 3, 2024)
Webcast Link: https://s.comein.cn/n3arj55s

Alternatively, participants may dial into the conference call using below dial-in information:

United States:           [phone]
                                  [phone]
Chinese Mainland:    400-969-8928
                                  400-806-3263
Hong Kong, China:   [phone]
Taiwan, China:          [phone]
                                  [phone]
Singapore:                [phone]
                                  [phone]
United Kingdom:       [phone]
International:             [phone]
Password:                 377570

The replay of English session will be available shortly after the call and can be accessed by visiting the Company's website at http://www.everestmedicines.com.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

References:

Overall clinical remission (complete remission or partial remission): 24h proteinuria complete remission (CR): 24h proteinuria < 0.3g/24 h; 24h proteinuria partial remission (PR): 24h proteinuria < 3.5g/24h, but ?0.3g/24 h, and reduction > 50%, regardless of eGFR or the serum albumin level from baseline.Immunological complete remission (ICR): anti-PLA2R titer < 20RU/ml (negative).Expert consensus on the application of rituximab in the treatment of membranous nephropathy, Chin J Intern Med, March 2022, Vol. 61, No. 3.

 

View original content:https://www.prnewswire.co.uk/news-releases/everest-medicines-announces-positive-results-in-preliminary-analysis-of-phase-1b2a-clinical-trial-of-ever001-a-novel-btk-inhibitor-for-the-treatment-of-primary-membranous-nephropathy-302321799.html